6.2.1.1. indications “cold knife” direct vision internal urethrotomy. 6.2.1.1.1. direct vision internal urethrotomy primary stricture treatment high-level evidence study, steenkamp et al., randomised 210 patients seemingly comparable non-obliterative strictures locations urethra either filiform dilatation vs. dviu local anaesthesia outpatient basis . collected objective data rug performed seven follow-up visits (3, 6, 9, 12, 24, 36 48 months). unique study showed urethral dilatation equally effective dviu procedure modalities become less effective increasing stricture length (see section 6.2.1.1.3.1). retrospective cohort series primary treatment patients iatrogenic urethral strictures reported significantly poorer patency rate dviu compared urethroplasty techniques (32.2 versus 82.4-83.5%) . patency rates vary considerably 8% 77% dviu (predominantly without prior urethroplasty) retrospective cohort studies minimum follow-up one year [67,198-204] (table 6.1). median time recurrence less twelve months series [67,198-202]. large variation patency rate part explained heterogeneous nature strictures various definitions patency used authors series. indication perform dviu dependent various stricture characteristics prognostic successful outcome. table 6.1: results dviu series minimum follow-up > 12 months studynage (years)follow-up (months)locationlength (cm)previous interventionsttr (months)patency rate (%)al taweel et al. 30137 (range: 17-82)36bulbar: 227 (75%)1.3 (0.4-4.2)primary: 47%108.3penile: 50 (17%)recurrent: 53%--penobulbar: 24 (8%)barbagliet al. 13637 (iqr: 25-48)55 (range: 36-92)bulbar: 100%1-2 cm: 45%primary: 100%25572-3 cm: 40%3-4 cm: 15%kluth et al. 12864 (sd: 16)16 (iqr:6-43)penile: 15 (12)nrprimary: 66%852bulbar: 112 (88)recurrent: 34%--unknown: 1 (1%)pal et al. 18639 (sd:15)1st dviu: 58 (sd: 15)bulbar: 100%nrprimary: 69%8.51stdviu: 302nd dviu: 56 (sd: 15)repeat: 31%-2nddviu: 233rd dviu: 45 (sd: 15)3rddviu: 13launonen et al. 346 (range: 0-16)79 (range: 7-209)bulbar: 74%< 2 cm: 85%primary: 100%426%penile: 21%> 2 cm: 15%penobubar: 6%-redon-galvezet al. 6757 (range: 15-91)40 (range: 12-120)penile:9%< 1 cm: 82%primary: 90%< 2463%bulbar: 64%> 1 cm: 18%repeat: 10%--vua: 21%membranous: 6%güler y. 23457 (range: 22-74)47 (range: 24-56)penile: 34%2.5 (0.4-5)primary: 100%-34%bulbar: 59%30%membranous: 6%33%harrazet al. 43050 (sd: 15)29 (range: 3-132)bulbar: 100%< 2 cmnr, prior urethroplasty excludednr58%yürüket al. 19365 (sd: 13)36 (sd: 12)bulbar: 100%< 1 cm: 140 (73%)0%87% recurrence < 377%1-2 cm:21 (11%)-100% recurrence < 6-2-3 cm:32 (17%) dviu = direct vision internal urethrotomy; iqr = interquartile range; n = number patients; nr = reported; sd = standard deviation; ttr = time recurrence. 6.2.1.1.2. direct vision internal urethrotomy recurrent strictures salvage treatment failed urethroplasty open trial, recurrent stricture defined least one previous failed intervention (endoscopic urethrotomy, urethral dilatation, urethroplasty) . previous intervention predominantly dviu. despite poor recruitment, 108 112 patients randomised urethroplasty dviu respectively 24-month study protocol. groups similar improvement voiding score symptoms intervention. however, patients undergoing urethroplasty 2.6 higher odds experiencing improvement > 10 ml/s maximum urinary flow compared undergoing urethrotomy (p=0.001) . need re-intervention observed 13.8% vs. 25.9% cases respectively allocated urethroplasty dviu resulting 48% lower risk re-intervention urethroplasty (hr: 0.52; 95% ci: 0.31-0.89; p=0.017) . note, self-dilatation considered re-intervention . despite re-interventions dviu group, treatments resulted similar improvement quality life higher cost urethroplasty limitation follow-up two years. . direct vision internal urethrotomy also used salvage treatment recurrent strictures urethroplasty. brown et al., used dviu stricture recurrence (mean length: 4 cm; range: 1.5-7 cm) excision primary anastomosis (epa), buccal mucosa grafts (bmg) urethroplasty penile skin graft urethroplasty . patency obtained thirteen 37 cases (35%) single dviu. free graft urethroplasty (fgu), short, veil-like stricture (or “diaphragm”) might develop distal proximal end graft. rosenbaum et al., used dviu selected cohort 43 patients short (< 1 cm), veil-like stricture bmg urethroplasty . mean follow-up twelve months, patency rate 51%. 6.2.1.1.3. predictors failure “cold knife” direct vision internal urethrotomy several groups tried identify prognostic factors predict patients likely fail initial treatment (table 6.2). absence well-designed, adequately powered multi-centre trials difficult answer question clinical factors predictive failure dviu men urethral strictures. however, based predictors evaluated above, one summarise best candidates previously untreated patients single, short (max. 2 cm) bulbar stricture. barbagli et al., reported five-year patency rate 71% patients untreated short (1-2 cm) bulbar urethral strictures . table 6.2: predictors urethral patency direct vision internal urethrotomy authorlocationlengthcalibremultiplicityprior dviusteenkamp et al. / heyns rr recurrence penile vs. bulbar: 1.85 (95% ci: 0.94 3.67, p = 0.077)< 2 cm: 60% (@12 months)nrnrnone: 50-60%(@48 months)-2-4 cm: 50% (@12m)--1: 0-40% (@48 months)-> 4 cm: 20% (@12 months)--2: 0% (@24 months)al taweel et al. bulbar: 11%< 1 cm: 27%nrnr0: 12.1%penile: 0%1-2 cm: 0%--1: 7.9%penobulbar: 0%> 2 cm: 0%--> 1: 0%barbagli et al. na1-2 cm: 71% (@60 months)pqmax< 5 ml/s: 31%na0: 62%-2-3 cm: 51%(@60 months)pqmax5-8 ml/s: 53%-1: 37%-3-4 cm: 39%(@60 months)pqmax> 8 ml/s: 83%--kluth et al. location predictornrpqmax predictornr0: 60%----> 1: 39%pal et al. na< 1 cm: 45%nrsingle: 35%0: 30%-1-1.5 cm: 0%-multiple: 0%1: 23%-> 1.5 cm: 0%--2: 13%launonen bulbar: 76%*< 2 cm: 83%*nrnr0: 26%penile: 71%*> 2 cm: 0%*--1: 33%----2: 26%----3: 11%----4: 0%redon-galvez nr< 1 cm: 71%nrnrnr-> 1 cm: 25%---güler bulbar: 30%<1.85 cm: 0.86 (95% ci:0.74-0.99; p=0.042)nrnrnrpenile: 34%membranous: 33% dviu = direct vision internal urethrotomy; na = applicable; nr = reported; pqmax = pre-operativemaximum urinary flow; rr: relative risk; or: odds ratio; ci: confidentialtiy interval.*patency rates reported repetitive treatments.